Global Markets Direct’s, ‘BioLingus AG - Product Pipeline Review - 2016’, provides an overview of the BioLingus AG’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG - The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses BioLingus AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features BioLingus AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate BioLingus AG’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for BioLingus AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding BioLingus AG’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
“MT-102 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Cancer Cachexia in 7 Major Markets. A detailed picture of the MT-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period...
“TTHX 1114 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Fuchs Endothelial Dystrophy in 7 Major Markets. A detailed picture of the TTHX 1114 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D...
The global flip (Flipped) classroom market reached a value of US$ 1.35 Billion in 2020. A flip classroom is an innovative teaching model where the learning takes place through an online mode rather than the conventional classroom mode of teaching. In this setup, students watch live or pre-recorded lectures, work together with fellow students...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Premature Ejaculation Treatment Market 2021-2025 The analyst has been monitoring the premature ejaculation treatment market and it is poised to grow by $ 1.29 bn during 2021-2025, progressing at a CAGR of 10% during the forecast period. Our report on premature ejaculation treatment market provides a holistic analysis,...
2021 Global Microbiology Market--SWOT Analysis and Supplier Shares by Country, Strategic Profiles of Leading Competitors and Emerging Market Entrants This new 90-page report provides insightful profiles of leading microbiology market players and recent market entrants.The report is available by section, and...
“Tadekinig Alfa- Emerging Insight and Market Forecast – 2030” report provides comprehensive insights about an investigational product for Hemophagocytic Lymphohistiocytosis (HLH): Primary HLH, Secondary HLH, and Adult-onset Still’s Disease (AoSD) in Seven Major Markets. A detailed picture of the Tadekinig Alfa in Seven Major Markets, i.e.,...
What’s Driving the Consumer Goods Industry?--The Road to 2025 and Beyond--SWOT Analysis The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: Organization and Management,...
2021 Leading Cosmetics Companies SWOT Analysis--Capabilities, Goals and Strategies
This report is part of the Competitive Analysis Series prepared to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to the leading competitors.
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.